KDA Group Adds Member to its Strategic Advisory Board

Tickers: XTSX:KDA
Tags: #Mining

Thetford Mines, Quebec - TheNewswire - July 13, 2020 - KDA Group Inc. (TSXV:KDA) ("KDA" or the "Corporation") is pleased to announce the addition of Mr. Anthony Rail as a member of its strategic advisory board (the "Strategic Board").

"We are proud that Mr. Rail has agreed to join KDA's Strategic Board. He will bring a leading and unique expertise in information technology, which will help ensure the proper direction and progress of projects' development," said Marc Lemieux, Chief Executive Officer of KDA.

Mr. Rail is co-founder and currently Director of Technology at SimplyPhi Solutions, a Quebec-based company involved in the research of new technologies using artificial intelligence, particularly in the medical field, automation and business process optimization.

Mr. Rail has extensive experience in advanced technologies such as the Blockchain (data immutability), computer security, business technologies and artificial intelligence. In addition, Mr. Rail acts as a technology consultant for multiple companies to improve the effectiveness of marketing, operations and products.

As Director of Technology, Mr. Rail leads the preparation of a data center according to the highest industry standards, aiming to achieve several standards including HIPAA (United States) and PIPEDA (Canada). Located in Quebec, this high-performance data center has a major computing power allowing the training of models and their inferences.

Mr. Rail is also involved in several business sectors, allowing him to have an excellent knowledge of the implication of technologies at the B2B, B2B2C and B2C levels.

The Strategic Board is comprised of respected business leaders who provide guidance and assistance to KDA's management team in their efforts and decision-making to build, strengthen and grow its business model.

The inaugural members of KDA's Strategic Board were as follows:

Sylvain Duvernay - Mr. Duvernay holds a Bachelor's degree in Business Administration and a Certificate in International Trade. He has over 20 years of experience in pharmaceutical and international business.

Mr. Duvernay filled the position of Vice-President for Strides Arcolab Ltd a pharmaceutical generic product company involved in softgel, injectable and solid dose manufacturing. He led its Canadian operations as well as its business development in the United States.

In 2008, Sylvain was behind the acquisition of the Bristol-Myers Squibb facility in Candiac where he developed a business model for the injectable business and acted as the President and CEO for the new entity, Uman Pharma Inc.

The company was sold to Pharmascience in November 2014. He stayed two years for the integration before moving to Capcium, a softgel manufacturing company for the pharmaceutical and nutraceutical sectors.

As Capcium's CEO, he leads the strategy and the construction of a state-of-the-art facility that will meet FDA, EMA and Health Canada standard.

Jean-Pierre Robert - Mr. Robert is very much involved in the post-COVID-19 preparations for the pharmaceutical and medical equipment sectors.

Mr. Robert has held several positions including Executive Vice President of Tyco Healthcare/Mallinckrodt Canada (now Medtronic) from 1996 to 2003 and President and Chief Operating Officer of Draxis Specialty Pharmaceuticals Inc. from 2005 to 2010. From 2010 to 2016, he served as President, CEO and Chairman of the Board at Cadens Medical Imaging (now Imagia Cybernetics). Since 2016, Mr. Robert has held the position of President of Campus des Technologies Medicales (CTS), an accelerator that provides start-up companies with a structured environment to help them achieve market momentum and international exposure.

Having completed part of his MBA at Montreal HEC and his Bachelor's degree in Chemistry at the Montreal University, Jean-Pierre has distinguished himself as a generator of innovative ideas and concepts and as a negotiator during corporate acquisitions and mergers.

In addition, he is actively involved in several business networks as an advisor to facilitate negotiation of commercial and strategic agreements at an international level and sits on several boards of directors.

The Corporation's management may modify and add other members to its Strategic Board at any time and place according to its needs and the specific expertise required and sought out from each new member.


KDA Group is a leading innovation and specialized solution provider in the pharmaceutical market. Today, it is a respected name for quality and expertise among the different stakeholders in the pharmaceutical and medical sector. Its management team is guided by a vision of continuing to lead the way in Quebec while extending operations across Canada and internationally. Additional information on the Corporation is available at www.kdagroup.ca and on SEDAR at www.sedar.com.

- 30 -


This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.


Marc Lemieux

Chief Executive Officer

514 622-7370


Copyright (c) 2020 TheNewswire - All rights reserved.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.